Perhaps they got the footnote wrong and it should have said 2019...

Perhaps they got the footnote wrong and it should have said 2019 (per the announcement in August 2019).

A snippet from the Annual Report (hopefully approvals are imminent)

Three products under review by FDADuring the year, Acrux had its third dossier accepted for
review by the FDA and this is currently under active review
along with two additional dossiers previously submitted. For
each submitted product dossier the Company has received
minor Complete Response Letters from the FDA and once
satisfactory responses are reviewed by the FDA, we expect
product approvals to be forthcoming.